Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308232 | 0.85 | RAB9A (0.55) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6308077 | 0.83 | HTR1A (0.53) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6308342 | 0.82 | CHRM1 (0.62) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6305703 | 0.82 | CHRM1 (0.53) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6305863 | 0.81 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6308881 | 0.76 | WDR5 (0.55) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6308941 | 0.76 | NPC1 (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL6308769 | 0.75 | NPC1 (0.60) | KMT2ANPC1RAB9AMAPTMAPK1 | |
| SCHEMBL8186032 | 0.75 | HTR5A (0.53) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL6306747 | 0.75 | NPC1 (0.49) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | MEN1 2395/4885KMT2A 2512/4885NPC1 629/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | MEN1 1146/4885KMT2A 3180/4885NPC1 955/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | MEN1 1856/4885KMT2A 2326/4885NPC1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.